Critical Survey: MediciNova (NASDAQ:MNOV) and Xeris Biopharma (NASDAQ:XERS)

Xeris Biopharma (NASDAQ:XERS) and MediciNova (NASDAQ:MNOV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability.

Risk & Volatility

Xeris Biopharma has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.

Institutional & Insider Ownership

42.7% of Xeris Biopharma shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 4.3% of Xeris Biopharma shares are held by insiders. Comparatively, 14.0% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Xeris Biopharma and MediciNova”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$335.41 million	5.46	$550,000.00	($0.11)	-91.39
MediciNova	$410,000.00	179.11	-$12.00 million	($0.21)	-7.10

Xeris Biopharma has higher revenue and earnings than MediciNova. Xeris Biopharma is trading at a lower price-to-earnings ratio than MediciNova, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Xeris Biopharma and MediciNova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
MediciNova	-1,168.70%	-26.51%	-24.39%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Xeris Biopharma and MediciNova, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1	2	4	0	2.43
MediciNova	1	1	4	1	2.71

Xeris Biopharma currently has a consensus target price of $13.20, suggesting a potential upside of 31.30%. MediciNova has a consensus target price of $7.75, suggesting a potential upside of 419.44%. Given MediciNova’s stronger consensus rating and higher probable upside, analysts plainly believe MediciNova is more favorable than Xeris Biopharma.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

About MediciNova

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.